Dr. Akhilesh Vats

Dr. Akhilesh Vats is a pharmaceutical scientist, formulation researcher, founder of ACME Research Solutions, ISEF Qualified Scientist 2026, and Editor-in-Chief at PEXACY International Journal of Pharmaceutical Science. He also serves as an editor at The Witfire Elite Pharma News, where his editorial focus is to make pharma news more useful for serious readers by adding scientific context, regulatory interpretation, market consequence, and business-level meaning.

Moderna flu vaccine mFlusiva under FDA review after refusal-to-file reversal

Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice

/ FDA & Regulatory Intelligence, Pharma News /

Moderna Flu Vaccine: From FDA Refusal to Two 9-0 Votes | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Moderna Flu Vaccine Reversal FDA Refused to Review It—Then Advisers Voted 9-0 Twice Four months after FDA refused to file Moderna’s application, its vaccine […]

Moderna Flu Vaccine Reversal: FDA Refused to Review It—Then Advisers Voted 9-0 Twice Read More »

GSK’s $10.6B Nuvalent Deal Why Big Pharma Bought Two FDA plants

GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy

/ FDA & Regulatory Intelligence, Pharma Market Case Studies, Pharma News /

GSK Did Not Simply Buy Nuvalent. It Bought Two FDA Decision Dates | Witfire Elite View Witfire Elite Oncology M&A Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View GSK Did Not Simply Buy Nuvalent It Bought Two FDA Decision Dates, a Shortcut into Lung Cancer, and Pre-Approval Regulatory Proximity GSK’s $10.6

GSK Bought September and November 2026: The $10.6 Billion Nuvalent Autopsy Read More »

FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma

/ FDA & Regulatory Intelligence /

FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma | Witfire Elite View Witfire Elite FDA & Regulatory Case Studies Strategy Long Read FDA & Regulatory Intelligence Witfire Elite View FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma Then the Door Reopened: A Regulatory Whiplash Case Study RP1 showed a roughly one-in-three

FDA Rejects Replimune’s RP1 Despite 34% Response Rate in Melanoma Read More »

India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent

India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent

/ Pharma Market Case Studies, Pharma News /

India CRO Boom: Why Chinese Molecules May Build the Next Outsourcing Wave | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View India CRO Boom Why Chinese Molecules May Build the Next Outsourcing Wave Western pharma wants Chinese innovation but less China execution risk. That

India CRO Boom: Why India’s Next CRO Boom May Be Built on Molecules It Did Not Invent Read More »

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead

/ Pharma Market Case Studies, Pharma News /

Iran War Pharma Shock: India API Dependence vs China Biotech Chokepoints | Witfire Elite View Witfire Elite Pharma Markets Case Studies Strategy Long Read Pharma Market Case Studies Witfire Elite View Iran War Pharma Shock Why India’s API Dependence Hurts More Than China’s Biotech Lead The Iran war and Strait of Hormuz disruption expose a

Iran War Pharma Shock: Why India’s API Dependence Hurts More Than China’s Biotech Lead Read More »

Scroll to Top